Shedding Light on nAMD: The Latest Advances in Treating Neovascular Age-Related Macular Degeneration

Shedding Light on nAMD The Latest Advances in Treating Neovascular AgeRelated Macular Degeneration
Media formats available:
Details
Presenters
  • Overview

    Join us for this live virtual symposium on neovascular age-related macular degeneration. Drs. Holekamp, Clark, and Kitchens will discuss strategies to incorporate cutting-edge treatments into practice and tips to identify which patients may benefit from next-generation therapies.

    This activity is supported by an educational grant from Genentech, a member of the Roche Group.

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Discuss current and future therapeutic agents for neovascular AMD, and the implications for patient outcomes
    • Identify patients who may benefit from the next generation of retinal disease therapies
    • Develop strategies to improve adoption of cutting-edge therapies for the treatment neovascular AMD into clinical practice
    • Accreditation

      Provided by Evolve Medical Education 

      Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
      Evolve designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

      Successful completion of this CME activity, which includes participation in the evaluation component, earns credit toward the Lifelong Learning requirement[s] for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting credit.

    • Participation Method

      In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

    • Faculty and Disclosures

      Nancy M. Holekamp, MD

      Nancy M. Holekamp, MD

      Director, Retina Services
      Pepose Vision Institute
      Chesterfield, MO


      W. Lloyd Clark, MD

      W. Lloyd Clark, MD

      Retina Specialist
      Palmetto Retina Center
      West Columbia, SC


      John W. Kitchens, MD

      John W. Kitchens, MD

      Partner

      Retina Associates of Kentucky

      Lexington, KY


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

      The following faculty/staff members have the following financial relationships with ineligible companies.

      Nancy M. Holekamp, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Allergan, Annexon, Apellis, Bayer, Cardinal, Clearside Biosciences, EyePoint Pharmaceuticals, Gemini Therapeutics, Gyroscope, Katalyst Surgical, Nacuity, NGM, Notal Vision, Novartis, Ocuphire, Outlook Therapeutics, Regeneron Pharmaceuticals, Stealth Biosciences, and Thea Laboratoires. Grant/Research Support: Gemini Therapeutics, Genentech, Gyroscope, and Notal Vision. Speaker’s Bureau: Allergan, Apellis, Genentech, Regeneron Pharmaceuticals, and Spark Therapeutics. Stock/Shareholder: Gemini Therapeutics, Katalyst Surgical, and Nacuity.

      W. Lloyd Clark, MD, has had a financial agreement or affiliation with the following ineligible companies in the form of Consultant: Genentech/Roche and Regeneron. Grant/Research Support: Genentech/Roche, Kodiak, and Regeneron. Speaker's Bureau: Genentech/Roche and Regeneron.

      John W. Kitchens, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Alimera Sciences, Apellis Pharmaceuticals, Bausch + Lomb, Bayer, Biogen, Carl Zeiss Meditec, Genentech, Kodiak Sciences, Notal Vision, Oculus, Optos, Outlook, and Regeneron. Speaker's Bureau: Alcon, Allergan, Alimera Sciences, Apellis Pharmaceuticals, Bausch + Lomb, Bayer, Biogen, Carl Zeiss Meditec, Genentech, Kodiak Sciences, Outlook, and Regeneron. Grant/Research Support: Kodiak Sciences, Genentech, and Regeneron. Shareholder: Kodiak Sciences, Outlook, and Vortex.

      The Evolve staff, planners, and reviewers have no financial relationships with ineligible companies.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Genentech, a member of the Roche Group.

       

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free